Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Alfred Witjes

Showing results (1-10 of 378) with videos related to

Pageof 38
Sort By:
European Urology|November 19, 2011
Prognosis of T1G3 bladder cancer: how well can we predict progression?J Alfred Witjes
European Urology|October 3, 2012
The impact of recurrent non-muscle-invasive bladder cancer on progressionJ Alfred Witjes
European Urology|November 4, 2020
Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality BenefitJ Alfred Witjes
Nature Reviews. Urology|November 25, 2015
Bladder cancer in 2015: Improving indication, technique and outcome of radical cystectomyJ Alfred Witjes
BJU International|July 1, 2015
Fluorescence cystoscopy: the end of biopsies for carcinoma in situ detection?J Alfred Witjes
European Urology|May 29, 2007
What is the optimal BCG dose in non-muscle-invasive bladder cancer?J Alfred Witjes
European Urology|March 29, 2022
Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness StudyJ Alfred Witjes
European Urology|October 9, 2018
Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need?J Alfred Witjes
European Urology|April 26, 2025
Follow-up for Non-muscle-invasive Bladder Cancer: Should the Guidelines Be Adapted?J Alfred Witjes
The Journal of Urology|January 28, 2020
Editorial CommentJ Alfred Witjes
Pageof 38

Showing results (1-10 of 378) with videos related to

Sort By:
Pageof 38
European Urology|November 19, 2011
Prognosis of T1G3 bladder cancer: how well can we predict progression?J Alfred Witjes
European Urology|October 3, 2012
The impact of recurrent non-muscle-invasive bladder cancer on progressionJ Alfred Witjes
European Urology|November 4, 2020
Re: Optimal Cystectomy Outcome: A Composite Measurement Evaluating Quality of Care and Mortality BenefitJ Alfred Witjes
Nature Reviews. Urology|November 25, 2015
Bladder cancer in 2015: Improving indication, technique and outcome of radical cystectomyJ Alfred Witjes
BJU International|July 1, 2015
Fluorescence cystoscopy: the end of biopsies for carcinoma in situ detection?J Alfred Witjes
European Urology|May 29, 2007
What is the optimal BCG dose in non-muscle-invasive bladder cancer?J Alfred Witjes
European Urology|March 29, 2022
Re: Oncological Benefit of Re-resection for T1 Bladder Cancer: A Comparative Effectiveness StudyJ Alfred Witjes
European Urology|October 9, 2018
Radiofrequency-induced Thermochemotherapy for Recurrent Non-muscle-invasive Bladder Cancer: A New Treatment for an Unmet Need?J Alfred Witjes
European Urology|April 26, 2025
Follow-up for Non-muscle-invasive Bladder Cancer: Should the Guidelines Be Adapted?J Alfred Witjes
The Journal of Urology|January 28, 2020
Editorial CommentJ Alfred Witjes
Pageof 38